Importer of Controlled Substances; Notice of Application, 160 [E9-31165]

Download as PDF 160 Federal Register / Vol. 75, No. 1 / Monday, January 4, 2010 / Notices for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application pwalker on DSK8KYBLC1PROD with NOTICES Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on November 5, 2009, Mylan Technologies Inc., 110 Lake Street, Saint Albans, Vermont 05478, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II: NUCLEAR REGULATORY COMMISSION Dated: December 17, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–31165 Filed 12–31–09; 8:45 am] In the Matter of: Certain Licensees Requesting Unescorted Access to Radioactive Material; Order Imposing Trustworthiness and Reliability Requirements for Unescorted Access to Certain Radioactive Material (Effective Immediately) BILLING CODE 4410–09–P I OFFICE OF NATIONAL DRUG CONTROL POLICY Paperwork Reduction Act; 30-Day Notice AGENCY: Office of National Drug Control Policy. The Office of National Drug Control Policy (ONDCP) proposes the collection of information concerning arrestee drug use. ONDCP invites interested persons to submit comments to the Office of Drug Schedule Management and Budget (OMB) Methylphenidate (1724) ................ II regarding any aspect of this proposed Fentanyl (9801) ............................ II effort. Type of Information Collection: New The company plans to import the collection. listed controlled substances for Title: Arrestee Drug Abuse Monitoring analytical research and clinical trials. (ADAM II) Program Questionnaire. Any bulk manufacturer who is presently, or is applying to be, Use: The information will support registered with DEA to manufacture statistical trend analysis. such basic class of controlled substance Frequency: Ten sites will each may file comments or objections to the conduct two cycles of surveys from 250 issuance of the proposed registration and may, at the same time, file a written arrestees per cycle. Annual Number of Respondents: request for a hearing on such application pursuant to 21 CFR 1301.43, 5000. and in such form as prescribed by 21 Total Annual Responses: 5000. CFR 1316.47. Average Burden per Response: 25 Any such comments or objections minutes. should be addressed, in quintuplicate, to the Drug Enforcement Total Annual Hours: 2,083. Administration, Office of Diversion Send comments to John Kraemer, Control, Federal Register Representative OMB Desk Officer for ONDCP, New (ODL), 8701 Morrissette Drive, Executive Office Building, Room 10235, Springfield, Virginia 22152; and must be Washington, DC 20503. Comments must filed no later than February 3, 2010. be received within 30 days. Request This procedure is to be conducted additional information by facsimile simultaneously with, and independent transmission to (202) 395–6562, of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted attention: Robert Cohen, ONDCP, Office of Research and Data Analysis. in a previous notice published in the Federal Register on September 23, 1975, Dated: December 29, 2009. (40 FR 43745–46), all applicants for Daniel R. Petersen, registration to import a basic class of Deputy General Counsel. any controlled substance in schedule I [FR Doc. E9–31132 Filed 12–31–09; 8:45 am] or II are, and will continue to be, BILLING CODE 3180–02–P required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements VerDate Nov<24>2008 17:11 Dec 31, 2009 Jkt 220001 [NRC–2009–0577; EA–09–293] PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 The Licensees identified in Attachment 1 1 to this Order hold licenses issued in accordance with the Atomic Energy Act (AEA) of 1954, as amended, by the U.S. Nuclear Regulatory Commission (NRC or Commission) or an Agreement State, authorizing them to perform services on devices containing certain radioactive material for customers licensed by the NRC or an Agreement State to possess and use certain quantities of the radioactive materials listed in Attachment 2 to this Order. Commission regulations at 10 CFR 20.1801 or equivalent Agreement State regulations require Licensees to secure, from unauthorized removal or access, licensed materials that are stored in controlled or unrestricted areas. Commission regulations at 10 CFR 20.1802 or equivalent Agreement State regulations require Licensees to control and maintain constant surveillance of licensed material that is in a controlled or unrestricted area and that is not in storage. II Subsequent to the terrorist events of September 11, 2001, the NRC issued immediately effective security Orders to NRC and Agreement State Licensees under the Commission’s authority to protect the common defense and security of the nation. The Orders required certain manufacturing and distribution (M&D) Licensees to implement Additional Security Measures (ASMs) for the radioactive materials listed in Attachment 2 to this Order (the radionuclides of concern), to supplement the existing regulatory requirements. The ASMs included requirements for determining the trustworthiness and reliability of individuals that require unescorted access to the radionuclides of concern. Section 652 of the Energy Policy Act of 2005, which became law on August 8, 2005, amended Section 149 of the AEA to require fingerprinting and a Federal Bureau of Investigation (FBI) 1 Attachment 1 contains sensitive information and will not be released to the public. E:\FR\FM\04JAN1.SGM 04JAN1

Agencies

[Federal Register Volume 75, Number 1 (Monday, January 4, 2010)]
[Notices]
[Page 160]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-31165]



[[Page 160]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this Section to a bulk manufacturer of a 
controlled substance in schedule I or II, and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of 
such a substance, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with 21 CFR 1301.34(a), this is notice 
that on November 5, 2009, Mylan Technologies Inc., 110 Lake Street, 
Saint Albans, Vermont 05478, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as an importer of the 
basic classes of controlled substances listed in schedule II:

------------------------------------------------------------------------
                             Drug                               Schedule
------------------------------------------------------------------------
Methylphenidate (1724).......................................         II
Fentanyl (9801)..............................................         II
------------------------------------------------------------------------

    The company plans to import the listed controlled substances for 
analytical research and clinical trials.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic class of controlled 
substance may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43, and in 
such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than February 3, 2010.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, (40 FR 43745-46), all 
applicants for registration to import a basic class of any controlled 
substance in schedule I or II are, and will continue to be, required to 
demonstrate to the Deputy Assistant Administrator, Office of Diversion 
Control, Drug Enforcement Administration, that the requirements for 
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: December 17, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-31165 Filed 12-31-09; 8:45 am]
BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.